BACKGROUND: Tacrolimus (FK506) and cyclosporine A (CsA) are widely used immunosuppressive agents after renal transplantation in the clinic.
OBJECTIVE: To investigate the effects of FK506 and CsA on inflammatory cytokines and blood lipid after renal transplantation.
METHODS: Totally 112 patients who received renal allograft for the first time were randomly divided into two groups. The CsA group received a triple therapy of CsA, mycophenolate mofetil and glucocorticoid. The FK506 group received a triple therapy of FK506, mycophenolate mofetil and glucocorticoid. 1-year survival rate, reversing rate, serum concentrations of interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, fasting plasma glucose and blood lipid were measured in the FK50 and CsA groups.
RESULTS AND CONCLUSION: In the FK506 group, 1-year survival rate and reversing rate were significantly higher, while acute rejection rate was significantly lower, compared with the CsA group (P < 0.05). In the FK506 group, serum concentrations of IL-2, IL-6, IL-8 and fasting plasma glucose at 1 month and 1 year after transplantation were significantly higher compared with before transplantation (P < 0.05) and CsA group (P < 0.05). In the FK506 group, serum concentrations of IL-4 and IL-10 at 1 month and 1 year after transplantation were significantly lower compared with before transplantation (P < 0.05), but significantly higher compared with the CsA group (P < 0.05). In the FK506 group, total cholesterol, triacylglycerol and low density lipoprotein cholesterol at 1 month after transplantation were significantly higher compared with before transplantation (P < 0.05), but were significantly lower compared with the CsA group (P < 0.05). In the FK506 group, total cholesterol and low density lipoprotein cholesterol at 1 year after transplantation were significantly lower compared with CsA group (P < 0.05). These findings suggest that FK506 may reduce acute rejection and increase survival rate of renal transplantation via inhibiting the release of cytokines and improving glucose and lipid metabolisms.